This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.
Ulcerative colitis can be debilitating and unpredictable for the hundreds of thousands of people living with this chronic disease," said Caren Heller, chief scientific officer for the Crohn's &Colitis Foundation. ... Lilly is also studying mirikizumab in
susceptible are those with underlying co-morbidities like metabolic syndrome and cardiovascular disease. ... And then we have a whole ‘other’ group – patients with psoriasis, rheumatoid arthritis, Crohn’s disease, and also oncology patients.
position. There’s no specified timeline for that review to complete, but AbbVie says it has “entered into a timing agreement with FTC staff that would likely result” in a ... AZ licensed the drug – which is in late-stage testing for ulcerative
Intravenous Entyvio is already available in 60 countries. Takeda has reported updated results from a trial of its subcutaneous formulation of Entyvio in Crohn’s disease, showing activity over a year ... An enhanced clinical response rate – defined as
according to AbbVie outperformed its rival across all the trial’s primary and secondary outcome measures. ... It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as
treatments. It also indicated for use in adult patients with moderate-to-severe active Crohn’s Disease who have similarly had inadequate responses to standard treatments. ... after a lead-in period, were in remission from the inflammatory bowel disease
More from news
Approximately 20 fully matching, plus 153 partially matching documents found.
with Crohn’s disease or ulcerative colitis is expected to rise by around 25% by 2025, according to recent studies. ... This will help physicians take much better care of patients for something that is a lifetime disease.”.
Client:SCITERION. Agency:N/A. Campaign:4 Sites: Navigating the course ahead. Timescale:N/A. Crohn’s disease – a chronic, debilitating and progressive disease – is on the increase worldwide, but remission
The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other
Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to
Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
in phase III trials for complex perianal fistulas in Crohn's disease.
Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical
His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
The other side of … Crohn’s disease. “After visiting about seven doctors in two different countries, I am confident to say that all can align on 2–3 points at most”. ... Meet Irene. Like millions of others worldwide (and an estimated 115, 000
We carried out a survey among patients who have any one of these conditions: chronic obstructive pulmonary disorder (COPD), ulcerative colitis (UC), Crohn’s disease (CD) and idiopathic pulmonary fibrosis (IPF). ... Interestingly, patients in all
Although there’s been an increase of inflammatory bowel disease (IBD) in underrepresented populations, there are still lots of misconceptions surrounding Crohn’s and ulcerative colitis among certain ethnic groups. ... Different ethnic groups are at
Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.
Cello Health Insight in partnership with Janssen Pharmaceuticals has won EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'. ... The winning entry focused on exploring the Crohn’s Disease and Ulcerative Colitis
More from PMHub
Approximately 4 fully matching, plus 13 partially matching documents found.
Valid Insight is an award-winning pharmaceutical global market access consultancy....